- Conditions
- Kidney Transplant, Diabetes Mellitus, Type 2, Diabetic Nephropathy
- Interventions
- Cyclosporin, Tacrolimus, 'Diabetes Education / Management'
- Drug · Behavioral
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 1
- States / cities
- Stanford, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 70
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Liver Transplant Rejection, Immunosuppression
- Interventions
- Blood Draw - Rapamycin, Blood Draw from Control Subjects, Blood Draw - CyA, Blood Draw - Tacrolimus, Blood Draw - MMF
- Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Liver Transplant Recipient, Living Donor (of the Respective Liver Transplant Recipient)
- Interventions
- darTregs, Acetaminophen, Diphenhydramine, Immunosuppression (IS) Withdrawal, Study Mandated Procedures
- Biological · Drug · Procedure
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 3
- States / cities
- San Francisco, California • Chicago, Illinois • Rochester, Minnesota
- Conditions
- Heart Transplant
- Interventions
- tocilizumab, Placebo, Standard of Care Triple IS
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 385 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 20
- States / cities
- Beverly Hills, California • La Jolla, California • Stanford, California + 15 more
- Conditions
- Kidney Diseases
- Interventions
- Anti-thymocyte globulin, Mycophenolate mofetil, Prednisone, Tacrolimus, Sirolimus
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2008
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation
- Interventions
- Melphalan, Sirolimus, Total Body Irradiation (TBI), Cyclophosphamide, Mycophenolate Mofeti, Fludarabine, Allogeneic HSCT, Mesna, Filgrastim
- Drug · Radiation · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years to 120 Years
- Enrollment
- 260 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2028
- U.S. locations
- 2
- States / cities
- Duarte, California • Bethesda, Maryland
- Conditions
- Neurodermatitis
- Interventions
- Dupilumab SAR231893, Placebo, Moisturizers, Low to medium potent topical corticosteroids, Topical calcineurin inhibitors
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 21
- States / cities
- Gilbert, Arizona • Fort Smith, Arkansas • Sacramento, California + 18 more
- Conditions
- Acute Rejection, Renal Transplantation
- Interventions
- Campath-1H, rituximab, myfortic
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Atopic Dermatitis
- Interventions
- pimecrolimus, topical medical device
- Drug · Device
- Lead sponsor
- Emer, Jason, M.D.
- Individual
- Eligibility
- 2 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Liver Transplant, Liver Transplantation
- Interventions
- Immunosuppression withdrawal
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 7
- States / cities
- San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 4 more
- Conditions
- Melasma
- Interventions
- Illuminate Cream
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Renal Transplantation
- Interventions
- Thymoglobulin, Campath-1H, Daclizumab
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Delayed Graft Function, Kidney Transplant
- Interventions
- Belatacept, Calcineurin Inhibitor
- Drug
- Lead sponsor
- Nair, Vinay, D.O.
- Individual
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Primary Membranous Nephropathy
- Interventions
- Povetacicept, Tacrolimus
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 27
- States / cities
- Montgomery, Alabama • Surprise, Arizona • Los Angeles, California + 23 more
- Conditions
- Sickle Cell Disease
- Interventions
- Conditioning Regimen with Bone Marrow Transplant
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 16 Years to 40 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 8
- States / cities
- Oakland, California • Washington D.C., District of Columbia • Miami, Florida + 4 more
- Conditions
- End-Stage Renal Disease
- Interventions
- Daclizumab, Methylprednisolone/prednisone, Mycophenolate mofetil, Sirolimus, Bactrim, Ganciclovir, Lipitor
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 1
- States / cities
- Rockville, Maryland
- Conditions
- Adolescent Lupus Nephritis, Pediatric Lupus Nephritis
- Interventions
- voclosporin
- Drug
- Lead sponsor
- Aurinia Pharmaceuticals Inc.
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- BK Viremia, BK Nephropathy
- Interventions
- Tacrolimus, Mycophenolate acid, Sirolimus
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- End-Stage Renal Disease, Living Donors
- Interventions
- Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 14 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Diabete Type 1, Chronic Kidney Disease
- Interventions
- Tegoprubart, Islet Cell Transplant
- Drug · Biological
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2030
- U.S. locations
- 2
- States / cities
- Miami, Florida • Chicago, Illinois
- Conditions
- Graft Versus Host Disease
- Interventions
- RGI-2001, Calcineurin Inhibitors, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning Regimen, Allogeneic Bone Marrow Transplantation, Methotrexate, Mofetil Mycophenolate, sirolimus
- Drug · Procedure
- Lead sponsor
- Regimmune Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 6
- States / cities
- San Diego, California • Stanford, California • Tampa, Florida + 3 more
- Conditions
- Renal Transplantation, Graft Rejection
- Interventions
- Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 19
- States / cities
- Little Rock, Arkansas • Los Angeles, California • San Diego, California + 13 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Allogeneic Pancreatic Islet Cells, Sirolimus, Basiliximab, Tacrolimus, Antibacterial, Antifungal, and Antiviral Prophylaxis, Trimethoprim/sulfamethoxazole, Clotrimazole, Valganciclovir, Heparin, Enoxaparin, Pentoxifylline, Aspirin
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Chronic GVHD
- Interventions
- Sirolimus + calcineurin inhibitor + prednisone, Sirolimus + prednisone
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- Not listed
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 31
- States / cities
- Duarte, California • La Jolla, California • Stanford, California + 27 more